Med24
overweight-obesity 1. 8. 2026 • 2 min read • JACC. Advances

Bariatric Surgery Improves Cardiac Remodeling and Function in Adults With Preserved Left Ventricular Ejection Fraction

Background Obesity is a risk factor for heart failure. Surgical treatment of obesity may help prevent heart failure. Objectives We examine the effect of bariatric surgery on cardiac remodeling and function in adults with preserved left ventricular (LV) ejection fraction. Methods Thirty-eight individuals with severe...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This study investigated the impact of bariatric surgery on cardiac health in obese adults with preserved LV ejection fraction. The research included 72 participants: 38 individuals who underwent biliopancreatic diversion with duodenal switch and 34 individuals managed medically.

Key Clinical Findings

Participants’ age ranged from 48.5 to 83.3 years, with a mean age of 48.5 years, and a mean body mass index of 46.4 kg/m2. The study examined cardiac remodeling and function through conventional and speckle tracking echocardiography at baseline and 12 months. A significant percentage of total weight loss was observed in the surgical group, reaching 36.7% ± 7.1%. Improvements in obesity-related metabolic conditions were also noted.

Sponsored content

Study Conclusions

Significant reductions in LV mass and LV hypertrophy were associated with bariatric surgery. These changes were statistically significant. The study’s findings suggest a potential benefit of bariatric surgery in addressing obesity-related cardiac abnormalities. The research indicates that bariatric surgery may be a viable approach for preventing or reversing cardiac issues linked to obesity. Further, larger prospective studies are recommended to validate these results and explore the long-term clinical effects.”} p>

Original Scientific Source
JACC. Advances
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study
overweight-obesity

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Summary Background Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods We analysed genome-wide data...

28. 10. 2026 Read article →
The interpretation of body-composition metrics in obesity
overweight-obesity

The interpretation of body-composition metrics in obesity

Modern obesity care is increasingly therapeutic, longitudinal, and outcome-oriented, yet clinical assessment often remains centered on total body weight and BMI. Although BMI remains useful for screening and population-level risk stratification, it cannot characterize the biological heterogeneity of obesity or the...

26. 10. 2026 Read article →
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial
overweight-obesity

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Background Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to 2 and adiposity-related complications have not been characterized....

14. 10. 2026 Read article →
Advertisement